Mechanistic Evaluations on Sorafenib Induced Hypophosphatemia in Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 31 Dec 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Bayer
- 31 Aug 2018 Biomarkers information updated
- 19 Jan 2011 Planned end date changed from 1 Jun 2013 to 1 Jan 2014 according to ClinicalTrials.gov.
- 19 Jan 2011 Status changed from recruiting to discontinued according to ClinicalTrials.gov.